Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339452 · ClinicalTrials.gov registry record
Impella Supported OPCABG
A clinical trial of Ischemic Cardiomyopathy, sponsored by Lucian Archambault Durham III.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04339452: Active study of Ischemic Cardiomyopathy, sponsored by Lucian Archambault Durham III.
NCT04339452 is a study of Ischemic Cardiomyopathy that is active but no longer recruiting, run by Lucian Archambault Durham III. The registered enrollment target is 30 participants, below the 376-participant average among 10 other Ischemic Cardiomyopathy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04339452, a study of Ischemic Cardiomyopathy, is active but no longer recruiting, sponsored by Lucian Archambault Durham III.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study introduces a novel approach to coronary revascularization through the use of a short term minimally-invasive left ventricular assist device (LVAD) to minimize myocardial injury and eliminate low output state during the perioperative period
Primary Outcome
Intraoperative hemodynamic stability, defined as mean arterial pressure (MAP), cardiac index (CI), central venous pressure (CVP), and cerebral perfusion as measured by NIRS maintained within normal ranges for the entire operative time except potentially for short periods not exceeding 10 minutes in total time.
Conditions Studied
Interventions
- DEVICE Impella 5.5 with SmartAssist Supported OPCABG
Study Locations (1)
Wisconsin
- The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2026-03 |
What the registry record for NCT04339452 still lists
NCT04339452 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 376-participant average among 10 other Ischemic Cardiomyopathy trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Ischemic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which Impella 5.5 with SmartAssist Supported OPCABG is the first listed.
NCT04339452 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04339452 about?
NCT04339452 is a clinical study titled "Impella Supported OPCABG". The present study introduces a novel approach to coronary revascularization through the use of a short term minimally-invasive left ventricular assist device (LVAD) to minimize myocardial injury and eliminate low output state during the perioperative period
What is the current status of trial NCT04339452?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2022-05-11. Estimated completion is 2026-03.
What conditions does trial NCT04339452 study?
This clinical trial studies the following conditions: Ischemic Cardiomyopathy.
What interventions are being tested in trial NCT04339452?
The interventions under investigation include: Impella 5.5 with SmartAssist Supported OPCABG (DEVICE).
Who is sponsoring clinical trial NCT04339452?
This trial is sponsored by Lucian Archambault Durham III, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04339452 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04339452's enrollment target sits among peer trials
30 10th of 10 higher than 1 of 10 other Ischemic Cardiomyopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Left Ventricular Structural Predictors of Sudden Cardiac Death
RECRUITING
-
Implantable Cardioverter Defibrillator (ICD Registry)
RECRUITING
-
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
RECRUITING · NA
-
Phenotypic Classification of FMR With CMR
RECRUITING
-
Venous Ethanol for Ventricular Tachycardia
RECRUITING · Phase 2
-
Assessment of Combined CCM and ICD Device in HFrEF
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI